Corrigendum to “Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway” [Heliyon 9(6) (June 2023) e16696]

Detalles Bibliográficos
Autores principales: Qian, Xuemeng, Cai, Jiajing, Qi, Qi, Han, Jia, Zhu, Xinfang, Xia, Rong, Zhang, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559544/
https://www.ncbi.nlm.nih.gov/pubmed/37809970
http://dx.doi.org/10.1016/j.heliyon.2023.e19952
_version_ 1785117524037206016
author Qian, Xuemeng
Cai, Jiajing
Qi, Qi
Han, Jia
Zhu, Xinfang
Xia, Rong
Zhang, Qi
author_facet Qian, Xuemeng
Cai, Jiajing
Qi, Qi
Han, Jia
Zhu, Xinfang
Xia, Rong
Zhang, Qi
author_sort Qian, Xuemeng
collection PubMed
description
format Online
Article
Text
id pubmed-10559544
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105595442023-10-08 Corrigendum to “Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway” [Heliyon 9(6) (June 2023) e16696] Qian, Xuemeng Cai, Jiajing Qi, Qi Han, Jia Zhu, Xinfang Xia, Rong Zhang, Qi Heliyon Corrigendum Elsevier 2023-09-09 /pmc/articles/PMC10559544/ /pubmed/37809970 http://dx.doi.org/10.1016/j.heliyon.2023.e19952 Text en © 2023 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Corrigendum
Qian, Xuemeng
Cai, Jiajing
Qi, Qi
Han, Jia
Zhu, Xinfang
Xia, Rong
Zhang, Qi
Corrigendum to “Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway” [Heliyon 9(6) (June 2023) e16696]
title Corrigendum to “Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway” [Heliyon 9(6) (June 2023) e16696]
title_full Corrigendum to “Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway” [Heliyon 9(6) (June 2023) e16696]
title_fullStr Corrigendum to “Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway” [Heliyon 9(6) (June 2023) e16696]
title_full_unstemmed Corrigendum to “Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway” [Heliyon 9(6) (June 2023) e16696]
title_short Corrigendum to “Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway” [Heliyon 9(6) (June 2023) e16696]
title_sort corrigendum to “preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the pten/akt/mtor pathway” [heliyon 9(6) (june 2023) e16696]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559544/
https://www.ncbi.nlm.nih.gov/pubmed/37809970
http://dx.doi.org/10.1016/j.heliyon.2023.e19952
work_keys_str_mv AT qianxuemeng corrigendumtopreoperativefibrinogenisassociatedwiththeclinicalsurvivalofprimarylivercancerpatientsandpromoteshepatomametastasisviatheptenaktmtorpathwayheliyon96june2023e16696
AT caijiajing corrigendumtopreoperativefibrinogenisassociatedwiththeclinicalsurvivalofprimarylivercancerpatientsandpromoteshepatomametastasisviatheptenaktmtorpathwayheliyon96june2023e16696
AT qiqi corrigendumtopreoperativefibrinogenisassociatedwiththeclinicalsurvivalofprimarylivercancerpatientsandpromoteshepatomametastasisviatheptenaktmtorpathwayheliyon96june2023e16696
AT hanjia corrigendumtopreoperativefibrinogenisassociatedwiththeclinicalsurvivalofprimarylivercancerpatientsandpromoteshepatomametastasisviatheptenaktmtorpathwayheliyon96june2023e16696
AT zhuxinfang corrigendumtopreoperativefibrinogenisassociatedwiththeclinicalsurvivalofprimarylivercancerpatientsandpromoteshepatomametastasisviatheptenaktmtorpathwayheliyon96june2023e16696
AT xiarong corrigendumtopreoperativefibrinogenisassociatedwiththeclinicalsurvivalofprimarylivercancerpatientsandpromoteshepatomametastasisviatheptenaktmtorpathwayheliyon96june2023e16696
AT zhangqi corrigendumtopreoperativefibrinogenisassociatedwiththeclinicalsurvivalofprimarylivercancerpatientsandpromoteshepatomametastasisviatheptenaktmtorpathwayheliyon96june2023e16696

Ejemplares similares